GlassScriptPhysician profile
Sabih Alam
NPI 1700346350
$1,960.04
in general payments reported to CMS, 2019-2025
29 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.55 · 2021: $15.44 · 2022: $247 · 2023: $832 · 2024: $382 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $369.02 | 2023-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $213.74 | 2020-2025 | Ozempic, Rybelsus |
| Amgen INC. | $206.44 | 2022-2024 | Otezla, Repatha |
| Gilead Sciences, INC. | $149.49 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.74 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.02 | 2023-2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $90.42 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $66.62 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $64.67 | 2024-2025 | Proclaim |
| Medtronic, INC. | $59.98 | 2023-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Alkermes, INC. | $55.11 | 2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.17 | 2025 | Caplyta |
| Exact Sciences Corporation | $44.77 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $42.16 | 2023 | Xarelto |
| Astellas Pharma US INC | $33.83 | 2024 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.53 | 2024-2025 | Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $29.38 | 2023-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Otsuka America Pharmaceutical, INC. | $29.15 | 2023 | Rexulti |
| Phathom Pharmaceuticals, INC. | $28.98 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $26.94 | 2022 | |
| Axsome Therapeutics, INC. | $23.85 | 2024 | Auvelity |
| Vertex Pharmaceuticals Incorporated | $21.96 | 2025 | |
| Vanda Pharmaceuticals INC. | $20.62 | 2024 | Fanapt |
| Novartis Pharmaceuticals Corporation | $16.77 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.17 | 2024 | Trintellix |
| Aimmune Therapeutics, INC. | $15.92 | 2025 | Zenpep |
| Xeris Pharmaceuticals, INC. | $15.44 | 2021 | |
| Dexcom, INC. | $14.63 | 2023 | Dexcom G6 Transmitter |
| Jazz Pharmaceuticals INC. | $14.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabih Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.